Plasma cyclic nucleotide levels in patients with refractory anaemia with excess of blasts.
To verify the clinical usefulness of extracellular cyclic nucleotide determinations as tumour markers in preneoplastic syndromes, plasma cyclic AMP (cAMP) and cyclic GMP (cGMP) levels were monitored in 47 patients with refractory anaemia with excess of blasts (35 RAEB and 12 RAEBt), 20 of whom progressed to acute leukaemia during the observation period. The control group consisted of 45 healthy subjects matched for age and sex. In all groups of patients plasma cAMP levels were within the normal range, whereas plasma cGMP levels were significantly higher than those of normal subjects in both RAEB and RAEBt patients, and increased further when progression to acute leukaemia occurred. These data suggest that serial determinations of plasma cGMP may be useful to monitor the progression of the disease, though there is no evidence that cGMP values at diagnosis may have a prognostic significance.
Peracchi
M
M
Istituto di Scienze Mediche, Università di Milano, Italy.
Bamonti-Catena
F
F
Bareggi
B
B
Calori
R
R
Maiolo
A T
AT
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000754:Anemia, Refractory, with Excess of Blasts / Q000097:blood*; D000242:Cyclic AMP / Q000097:blood*; D006152:Cyclic GMP / Q000097:blood*; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000097:blood; D008297:Male; D008875:Middle Aged; D011289:Preleukemia / Q000097:blood*
D000242:Cyclic AMP; D006152:Cyclic GMP